U006 Managing HS in Kids and Teens
DESCRIPTION
Over 50% of patients with hidradenitis suppurativa report onset of symptoms prior to age 21. Recognizing how to optimally treat HS is essential to intervening during a window of opportunity to prevent progression of disease. Adolescent patients can also have very severe HS that may require different considerations as compared to adults. This session will focus on the multifactorial nature of HS, how to identify phenotypes that may help direct treatment, and how to manage various systemic therapies.
LEARNING OBJECTIVES
Identify aspects of HS care that may differ between adults and children/adolescents and how to manage these differences
Assess pediatric patients and select systemic therapies based on that assessment, including those focused on insulin resistance, hormonal flares, and biologics.
DIRECTOR
Colleen Cotton, MD, FAAD
DISCLOSURES
Colleen Cotton, MD, FAAD
Amgen – Investigator(Grants/Research Funding); CorEvitas – Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Galderma – Advisory Board(Honoraria); HS Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Inner Archways LLC – Advisory Board(Other Financial Benefit); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Pierre Fabre – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);